SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

June 24, 2024

https://www.globenewswire.com/news-release/2024/06/24/2903035/0/en/SELLAS-Announces-U-S-FDA-Rare-Pediatric-Disease-Designation-Granted-to-SLS009-for-the-Treatment-of-Pediatric-Acute-Lymphoblastic-Leukemia.html

– Acute Lymphoblastic Leukemia (ALL) is the Most Common Type of Cancer in Children –

– Rare Pediatric Disease Designation (RPDD) Provides Eligibility for SLS009 to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties –

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.